Update on the use of deferasirox in the management of iron overload
Therapeutics and Clinical Risk Management, 2009 Ali Taher,1 Maria Domenica Cappellini21American University of Beirut, Beirut, Lebanon; 2Universitá di Milano, Policlinico Foundation IRCCS, Milan, ItalyAbstract: Regular blood transfusions as supportive care for patients with chronic anemia ...
Ali Taher, Maria Domenica Cappellini
doaj +3 more sources
Application of Fuzzy AHP for Medication Decision Making in Iron-Chelating Medications for Thalassemia [PDF]
PharmacyIron overload is a significant concern for patients with thalassemia and often necessitates the use of iron-chelating agents to mitigate the associated complications.
Saeed Barzegari +3 more
doaj +2 more sources
Fluvastatin suppresses hemin-induced cell death, reactive oxygen species generation, and elevated labile iron pool [PDF]
Hematology, Transfusion and Cell TherapyBackground: In transfusion-related iron overload, macrophage/reticuloendothelial cells are the first site of haem-derived iron accumulation. The prevention of haem-induced cytotoxicity in macrophages may represent a target for iron overload treatment ...
Shion Imoto +6 more
doaj +2 more sources
Pharmacogenomic and Clinical Predictors of Deferasirox Response in Transfusion-Dependent Thalassemia Identified Using Whole-Genome Sequencing. [PDF]
Clin Transl SciABSTRACT Deferasirox is a widely used oral iron chelator in patients with transfusion‐dependent thalassemia, but considerable variability in treatment response remains a clinical challenge. This study applied whole‐genome sequencing to investigate genetic predictors of deferasirox response in 88 Thai patients.
Yampayon K +11 more
europepmc +2 more sources
Bridging Pharmacokinetics and Pharmacodynamics: A PBPK/PD Model-Based Approach for Deferasirox Dosing in Transfusion-Dependent Thalassemia. [PDF]
Clin Transl SciSakares W +13 more
europepmc +2 more sources
Follow-Up of 3-Year Luspatercept Treatment in a Transfused ß-Thalassemia Patient. Bone Marrow: An Undervalued Iron Store. [PDF]
EJHaemABSTRACT Introduction Treatment with luspatercept may improve transfusion requirements in transfusion‐dependent thalassemia (TDT), but the improved erythroid maturation in the bone marrow influences body iron distribution. Case Report We report on sequential organ iron measurements in a TDT patient under luspatercept treatment.
Bleeke M +6 more
europepmc +2 more sources
Efficacy of combination chelation with deferasirox and deferiprone in children with beta-thalassemia major: an audit from a unit in the developing world. [PDF]
Clin Exp MedJames V, Prakash A.
europepmc +3 more sources
Development and Validation of a Method for Determining Deferasirox in Human Blood Plasma by HPLC-UV
Разработка и регистрация лекарственных средств, 2022 Introduction. Deferasirox is one of the most well-known complexing drugs chelators and is successfully used in chelating therapy for the treatment of excess iron in the human body. Deferasirox is also included in the list of vital and essential medicines,
P. A. Karpova +7 more
doaj +1 more source